OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY. (12th June 2019) - Le Gouill, S.; Beldi‐Ferchiou, A.; Cacheux, V.; Salles, G.; Canioni, D.; Bodet‐Milin, C.; Alcantara, M.; Delwail, V.; Gastinne, T.; Thieblemont, C.; Maisonneuve, H.; Lamy de la Chapelle, T.; et al.